Naloxone Mandate In Opioid Labels Divides US FDA Panel, Even As It Wants Patient Conversations

 
• By Derrick Gingery

Advisory committee members vote narrowly in favor of labeling opioids with a recommendation to co-prescribe naloxone, but more agree that the goal is to facilitate patient-provider dialogue about overdose risks.

FDA Advisory Committee Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers